我们的网站为什么显示成这样？

可能因为您的浏览器不支持样式，您可以更新您的浏览器到最新版本，以获取对此功能的支持，访问下面的网站，获取关于浏览器的信息：

|本期目录/Table of Contents|

三甲氧苄嗪对心肌缺血/再灌注损伤的保护作用(PDF)

《心脏杂志》[ISSN:1009-7236/CN:61-1268/R]

期数:
2002年第6期
页码:
469-471
栏目:
实验研究
出版日期:
2002-11-01

文章信息/Info

Title:
Protective effects of trimetazidine on myocardial ischemia-reperfusion injury
作者:
高思海;  李 平;  张凯伦;  杨辰垣
华中科技大学同济医学院附属协和医院心外科, 湖北武汉 430022
Author(s):
GAO Si-hai; LI Ping; ZHANG Kai-lun; YANG Chen-yuan
Department of Cardiovascular Surgery,Union Hospital,Tongji Medical College,Huazhong University of Science and Technology,Wuhan, Hubei 430022,China
关键词:
三甲氧苄嗪; 心肌缺血/再灌注损伤; 心肌保护
Keywords:
trimetazidine; myocardial reperfusion injury; myocardial protection
分类号:
R972.3;R542.22
DOI:
-
文献标识码:
A
摘要:
目的 探讨三甲氧苄嗪增补于停搏液中对缺血/再灌注离体鼠心的保护作用。方法 将24只Wistar大鼠随机分为三甲氧苄嗪组(A)和对照组(B)。离体鼠心在改良的Langendorff-Neely灌注模型上预灌注30 min,停搏120min、再灌注30 min。缺血前及再灌注期间测定血流动力学指标、心肌酶(CPK,LDH)、心肌超氧化物歧化酶(SOD)、过氧化脂质(LPO)含量、心肌ATP水平。电镜观察心肌超微结构。结果 再灌注后,A组心功能、心肌超微结构的改善,明显优于B组;心肌酶(CPK,LDH)、LPO含量显著低于B组(P<0.01);SOD含量和ATP水平显著高于B组(P<0.01)。结论 三甲氧苄嗪增补于停搏液中可显著减轻心肌缺血/再灌注损伤,具有良好的心肌保护作用。
Abstract:
AIM To study the protective effects of trimetazidine on myocardial ischemia-reperfusion injury.METHODS The study consisted of two groups of rats. Group A(n=12),received cardioplegia with trimetazidine. Group B(n=12),received same cardioplegia only. Isolated rat hearts were subjected to preperfusion for 30 min,ischemia for 120 min and reperfusion for 30 min using a modified Langendorff-Neely model with modified Krebs-Henseleit buffer at 37℃. The hemodynamic parameters, myocardial enzyme (CPK, LDH), myocardial superoxide dismutase (SOD),myocardial ATP level,myocardial lipid peroxide(LPO) and myocardial ultrastructure were measured before ischemia and during reperfusion.RESULTS Recovery of cardial function and myocardial ultrastructure in Group A was significantly better than Group B. Myocardial enzyme (CPK,LDH) and LPO in group A was significantly lower than in Group B(P<0.01). SOD was significantly higher than Group B(P<0.01). Myocardial ATP level was significantly higher than Group B(P<0.01).CONCLUSION Trimetazidine supplement in cadioplegia significantly alleviated reperfusion-mediated myocardial injury after global ischemia,suggesting good myocardio-protective actions.

参考文献/References

[1] Farrari H,Pepi P,Farrlari F,et al. Metabolic derangement in ischemic heart disease and its therapeutic control[J].Am J Cardiol,1998,82:2K-8K,

[2] Sentex E,Sergiel JP,Lucien H,et al. Is the crytoprotective ef- fect of trimetazidine associated with lipid metabolism? [J].AmJ Cardiol,1998,82:18K-24K.

[3] Taegtmeyer H, oodwin GW, Doenst T,et al. Substratemetabolism as a determinant for postischemic functional recovery of the heart[J].Am J Cardiol,1997,80(Suppl):3A-10A.

[4] Lagadic-Gossmann D, Le Progent K, Feuvray K. Effects of trimetazidine on regulation in the rat isolated vertricular myocyte[J].Br J Pharmacol,1996,117:831-838.

[5] Lopaschuk GD,Kozak R. Trimetazidine inhibits fatty acid oxidation in the heart[J].J Mol Cell Cardiol,1998,30:A122.

备注/Memo

备注/Memo:
收稿日期：2002-11-05.
更新日期/Last Update: 2002-11-01